What they were paid
Edgewise Therapeutics Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $55,000 | — | $304,477 | — | $359,477 |
| FY2024 | $48,227 | — | $247,738 | — | $295,965 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Edgewise Therapeutics, Inc. DEF 14A filed April 23, 2026, accession 0001104659-26-047688, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Edgewise Therapeutics pays directors a $40,000 cash retainer and $350,000 in Options.
Committees
FY2025 · as the proxy prints themCompensation (Chair)
The rest of the Edgewise Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Alan Russell, Ph.D | Director | $0 |
| Arlene M. Morris | Independent Director | $361,977 |
| Christopher Martin | Independent Director | $704,712 |
| Jonathan C. Fox, M.D., Ph.D | Independent Director | $349,477 |
| Jonathan Root, M.D | Independent Director | $359,477 |
| Kevin Koch, Ph.D | Director | $0 |
| Laura Brege | Independent Director | $371,977 |
| Peter Thompson, M.D | Director | $384,477 |
The full Edgewise Therapeutics compensation record
free company briefThis page is one director within Edgewise Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat